Bi- and trispecifics

Bispecific antibodies
#Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Roche

Roche acquires trispecific antibody for $1.5bn

Roche has acquired exclusive global rights to develop, manufacture, and commercialise SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.  Under the terms of the agreement, developer Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including $75 million in… Read More

#Business & Investment #News

Monoclonal antibody
#AbbVie #Autoimmune disease #Bi- and trispecifics #Mergers and acquisitions #Monoclonal antibodies #Oncology

AbbVie licenses trispecific antibody in billion-dollar contract

IGI Therapeutics, a wholly owned subsidiary of Ichnos Glenmark Innovation, and AbbVie have announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, for oncology and autoimmune diseases.  “Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by… Read More

#Business & Investment #News

#Antibodies #Bi- and trispecifics #Fc-Fusion proteins #Humanisation

Understand the critical design parameters for engineering antibody formats

This whitepaper includes an introduction to antibodies and the process of antibody engineering based on Absolute Antibody’s years of experience developing recombinant versions of antibodies for a range of clients. This whitepaper will be valuable to: Therapeutic antibody developers Researchers designing antibodies for diagnostics Researchers looking to refine assays,… Read More

#News